Preparation, characterisation and tumour targeting of cross-linked divalent and trivalent anti-tumour Fab' fragments
Authors:
Open Access
- 1 November 1996
- journal article
- research article
- Published by Springer Nature in British Journal of Cancer
- Vol. 74 (9) , 1397-1405
Abstract
The monoclonal anti-CEA antibody, A5B7, has previously been administered to patients for radioimmunotherapy (RIT). Long circulation time and the formation of an immune response have limited therapeutic success in the clinic. Antibody fragments can be used to reduce the in vivo circulation time, but the best combination of fragment and radioisotope to use for therapy is far from clear. In this study we have compared the biodistribution of A5B7 IgG and F(ab')2 with chemically cross-linked divalent (DFM) and trivalent (TFM) A5B7 Fab' fragments in nude mice bearing human colorectal tumour xenografts. The cross-linkers were designed to allow site-specific labelling using yttrium 90 (90Y), a high-energy beta-emitter. We have also compared the above antibody forms conjugated to both 131I and 90Y. Both DFM and TFM were fully immunoreactive and remained intact after radiolabelling and incubation in serum at 37 degrees C for 24 h. Biodistribution results showed similar tumour uptake levels and an identical blood clearance pattern for F(ab')2 and DFM with high tumour-blood ratios generated in each case. However, unacceptably high kidney accumulation for both F(ab')2 and DFM and elevated splenic uptake of DFM labelled with 90Y was observed. Kinetic analysis of antigen binding revealed that DFM had the fastest association rate (kass = 1.6 x 10(5) Ms-1) of the antibody forms, perhaps owing to increased flexibility of the cross-linker. This advantage implies that DFM may be more suitable than F(ab')2 radiolabelled with 131I for RIT. TFM cleared from the blood significantly faster than A5B7 IgG when labelled with both 131I and 90Y, producing an improved therapeutic tumour-blood ratio. Kidney accumulation was not observed for [90Y]TFM, but a slightly higher splenic uptake was observed that may indicate reticuloendothelial system (RES) uptake. Overall, tumour uptake was higher for 90Y-labelled antibodies than for 131I-labelled antibodies. Because of the faster clearance, it should be possible to administer a higher total dose of 90Y-labelled TFM than IgG, which is attractive for RIT. Both A5B7 DFM and TFM, therefore, show favourable properties compared with their parent antibody forms.Keywords
This publication has 39 references indexed in Scilit:
- Purification of bacterially expressed single chain Fv antibodies for clinical applications using metal chelate chromatographyJournal of Immunological Methods, 1995
- Recent developments in the radioimmunotherapy of cancerCurrent Opinion in Immunology, 1994
- Phage libraries for generation of clinically useful antibodiesThe Lancet, 1994
- Preparation, characterization, and in vivo biodistribution properties of synthetically cross-linked multivalent antitumor antibody fragmentsBioconjugate Chemistry, 1993
- High Level Escherichia coli Expression and Production of a Bivalent Humanized Antibody FragmentNature Biotechnology, 1992
- Different behaviour of mouse‐human chimeric antibody F(ab')2 fragments of IgG1, IgG2 and IgG4 sub‐class in vivoInternational Journal of Cancer, 1992
- Optimal antibody-radionuclide combinations for clinical radioimmunotherapy: a predictive model based on mouse pharmacokineticsInternational Journal of Radiation Applications and Instrumentation. Part B. Nuclear Medicine and Biology, 1991
- Antibody targeted therapy in cancer: comparison of murine and clinical studiesCancer Treatment Reviews, 1990
- Blood and tissue kinetics of radiolabeled anti-CEA monoclonal antibody and F(ab)2 and Fab fragments in nude mice with human tumour xenograftsNuclear Medicine Communications, 1989
- Radioimmunotherapy of human colon carcinoma by 131I‐labelled monoclonal anti‐cea antibodies in a nude mouse modelInternational Journal of Cancer, 1988